SULCONAZOLE NITRATE cream 1.0%

Manufacturer
JG Pharma | Journey Medical Corporation | DPT Laboratories, Ltd.
Effective date
2024-12-23
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
2
Source
full-release
Hydrated at
2026-05-31 21:20:24

Label at a glance#

ProductSulconazole Nitrate
Active ingredientSULCONAZOLE NITRATE
Label structure12 sections

Indications and uses

SULCONAZOLE NITRATE cream 1.0% is an antifungal agent indicated for the treatment of tinea pedis (athlete's foot), tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagro- phytes, Epidermophyton floccosum , and Microsporum canis ,* and for the treatment of tinea versicolor.

Dosage and administration

A small amount of cream should be gently massaged into the affected and surrounding skin areas once or twice daily, except in tinea pedis, where administration should be twice daily. Early relief of symptoms is experienced by the majority of patients and clinical improvement may be seen fairly soon after treatment is begun; however, tinea corporis/cruris and tinea versicolor should be treated for 3 weeks and tinea...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx only

For topical use only. Not for ophthalmic use.

DESCRIPTION

DESCRIPTION SECTION

SULCONAZOLE NITRATE cream 1.0% is a broad-spectrum antifungal agent intended for topical application. Sulconazole nitrate, USP, the active ingredient in SULCONAZOLE NITRATE cream, is an imidazole derivative with in vitroantifungal and antiyeast activity. Its chemical name is (±)-1-[2,4-Dichloro-β-[( p-chlorobenzyl)thio] phenethyl]imidazole mononitrate and it has the following chemical structure:

Chemical Structure
Chemical Structure

Sulconazole nitrate, USP is a white to off-white crystalline powder with a molecular weight of 460.77. It is freely soluble in pyridine; slightly soluble in ethanol, acetone, and chloroform; and very slightly soluble in water. It has a melting point of about 130°C.

SULCONAZOLE NITRATE cream contains sulconazole nitrate, USP 10 mg/g in an emollient cream base consisting of propylene glycol, stearyl alcohol, isopropyl myristate, cetyl alcohol, polysorbate 60, sorbitan monostearate, glyceryl stearate (and) PEG-100 stearate, ascorbyl palmitate, and purified water, with sodium hydroxide and/or nitric acid added to adjust the pH.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Sulconazole nitrate is an imidazole derivative with broad-spectrum antifungal activity that inhibits the growth in vitroof the common pathogenic dermatophytes, including Trichophyton rubrum, Trichophyton mentagro- phytes, Epidermophyton floccosumand Microsporum canis. It also inhibits ( in vitro) the organism responsible for tinea versicolor, Malassezia furfur. Sulconazole nitrate has been shown to be active in vitroagainst the following microorganisms, although clinical efficacy has not been established: Candida albicansand certain gram-positive bacteria.

A modified Draize test showed no allergic contact dermatitis and a phototoxicity study showed no phototoxic or photoallergic reaction to sulconazole nitrate cream. Maximization tests with sulconazole nitrate cream showed no evidence of contact sensitization or irritation.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

SULCONAZOLE NITRATE cream 1.0% is an antifungal agent indicated for the treatment of tinea pedis (athlete's foot), tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagro- phytes, Epidermophyton floccosum, and Microsporum canis,* and for the treatment of tinea versicolor.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

SULCONAZOLE NITRATE cream 1.0% is contraindicated in patients who have a history of hypersensitivity to any of its ingredients.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

SULCONAZOLE NITRATE cream 1.0% is for external use only. Avoid contact with the eyes. If irritation develops, the cream should be discontinued and appropriate therapy instituted.

Information for Patients

INFORMATION FOR PATIENTS SECTION

Patients should be told to use SULCONAZOLE NITRATE cream as directed by the physician, to use it externally only, and to avoid contact with the eyes.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Long-term animal studies to determine carcinogenic potential have not been performed. In vitrostudies have shown no mutagenic activity.

Pregnancy

PREGNANCY SECTION

There are no adequate and well-controlled studies in pregnant women. Sulconazole nitrate should be used during pregnancy only if clearly needed. Sulconazole nitrate has been shown to be embryotoxic in rats when given in doses of 125 times the adult human dose (in mg/kg). The drug was not teratogenic in rats or rabbits at oral doses of 50 mg/kg/day.

Sulconazole nitrate given orally to rats at a dose 125 times the human dose resulted in prolonged gestation and dystocia. Several females died during the prenatal period, most likely due to labor complications.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether sulconazole nitrate is excreted in human milk. Caution should be exercised when sul- conazole nitrate is administered to a nursing woman.

*Efficacy for this organism in the organ system was studied in fewer than 10 infections.

Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness in children have not been established.

Geriatric Use

GERIATRIC USE SECTION

Clinical studies of SULCONAZOLE NITRATE cream 1.0%, did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently than younger patients. Other reported clinical experience has not identified differences in responses between elderly and younger patients.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

There were no systemic effects and only infrequent cutaneous adverse reactions in 1185 patients treated with sulconazole nitrate cream in controlled clinical trials. Approximately 3% of these patients reported itching, 3% burning or stinging, and 1% redness. These complaints did not usually interfere with treatment.

CLINICAL STUDIES

CLINICAL STUDIES SECTION

In a vehicle-controlled study for the treatment of tinea pedis (moccasin type) due to T. rubrum, after 4 to 6 weeks of treatment 69% of patients on the active drug and 19% of patients on the drug vehicle had become KOH- and culture-negative. In addition, 68% of patients on the active drug and 20% of patients on the drug vehicle showed a good or excellent clinical response.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

A small amount of cream should be gently massaged into the affected and surrounding skin areas once or twice daily, except in tinea pedis, where administration should be twice daily.

Early relief of symptoms is experienced by the majority of patients and clinical improvement may be seen fairly soon after treatment is begun; however, tinea corporis/cruris and tinea versicolor should be treated for 3 weeks and tinea pedis for 4 weeks to reduce the possibility of recurrence.

If significant clinical improvement is not seen after 4 to 6 weeks of treatment, an alternate diagnosis should be considered.

HOW SUPPLIED

HOW SUPPLIED SECTION

SULCONAZOLE NITRATE cream 1.0% is a smooth, glossy white to off-white cream having a slight characteristic odor. It is supplied as follows:

            60 g tube - NDC 72143-311-60

Avoid excessive heat, above 40° C (104° F).

To report SUSPECTED ADVERSE REACTIONS, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Manufactured for:
JG Pharma
Scottsdale, AZ
85258
www.JGPharmainc.com

141079
September 2019

Principal Display Panel – 60g Carton Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

JG Pharma

NDC 72143-311-60

Rx only

sulconazole nitrate
cream, 1.0%

Net Wt. 60 g

Principal Display Panel – 60g Carton Label
Principal Display Panel – 60g Carton Label

Principal Display Panel – 60g Tube Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

JG Pharma

NDC 72143-311-60

Rx only

sulconazole nitrate
cream, 1.0%

Avoid excessive heat, above 40°C (104° F).

Net Wt. 60 g

For topical use only.

Not for ophthalmic use.

Principal Display Panel – 60g Tube Label
Principal Display Panel – 60g Tube Label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
106366sulconazole nitrate 1 % Topical CreamPSN2
106366sulconazole nitrate 10 MG/ML Topical CreamSCD2
106366sulconazole nitrate 1 % Topical CreamSY2

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
SULCONAZOLE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
312a1339-2d03-1da9-f090-a47730c5330aProduct name120140508
a4a028cc-e548-445b-8dc3-ebf42e7603dbProduct name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
72143-311-60Sulconazole Nitrate60 g in 1 TUBECREAM602
72143-311-60Sulconazole Nitrate1 in 1 CARTONCREAM12

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
72143-311SULCONAZOLE NITRATE CREAM [JG PHARMA]2Current NDC, Legacy NDC, 2 package rows20241225_5b731aa0-fb3f-4a96-9034-636138cbca03.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
72143-311-60GM - Gram72143-311a27eaeee-7030-4205-8580-0107185a426b12020-02-13

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 14 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
72143-31172143-311-60

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 13 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 44.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N018737-001EXELDERMSULCONAZOLE NITRATE1%CREAM / TOPICALRLD, RS1989-02-28

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 44 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-10-15 13:18:302026-09N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-28c2088c7a36db…
2026-09-14 22:38:342026-08N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-2884e616aacf4f…
2026-08-18 06:07:402026-07N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-28caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-28011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-2831067a03dcf5…
2025-08-23 18:47 UTC2025-08N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-286a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-28fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-28b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-2803ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-282680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-285bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-28d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-28d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-2879d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-28301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-281e350fbaab3a…
2024-05-31 18:47 UTC2024-05N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-288072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-285c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-285d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-284b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-2874a2ff9319b5…
2022-03-09 01:35 UTC2022-03N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-28bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-28782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-2887673890dc5c…
2021-03-12 10:30 UTC2021-03N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-285aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-288869cabd3fbd…
2020-11-12 02:37 UTC2020-11N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-28c0c555d07b60…
2019-12-14 00:12 UTC2019-12N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-283f01610625f2…
2019-09-15 20:21 UTC2019-09N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-28b00525d2431f…
2019-07-19 19:46 UTC2019-07N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-28ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-286a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-281c564ffb4f44…
2023-12-20 04:57 UTC2023-12N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-28ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-28a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-289b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-28a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-283f0d92c62455…
2023-05-13 08:27 UTC2023-05N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-28053a50430f4f…
2023-01-26 05:58 UTC2023-01N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-283bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11N018737-001EXELDERM1%CREAM / TOPICALRLD, RS1989-02-283a93d1ddd44b…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Sulconazole NitrateSULCONAZOLE NITRATEJG Pharma5b731aa0-fb3f-4a96-9034-636138cbca032024-12-23Adverse reactionsExact identifier
ndc (package): 72143-311-60
ndc (product): 72143-311
ndc11 (package): 72143031160
spl id: 29f5c965-1a31-83b6-e063-6394a90adc49
spl set id: 5b731aa0-fb3f-4a96-9034-636138cbca03

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.